Please login to the form below

Not currently logged in
Email:
Password:

Baxalta

This page shows the latest Baxalta news and features for those working in and with pharma, biotech and healthcare.

Immunology keeps Shire figures solid as Takeda takeover nears

Immunology keeps Shire figures solid as Takeda takeover nears

$612m but the company’s haematology franchise – including haemophilia products acquired along with Baxalta in 2016 – down 1% to $951m.

Latest news

More from news
Approximately 16 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    quite as fast as Shire's move to take over Baxalta when it was spun out of Baxter in July 2015).

  • The good, the bad and the ugly The good, the bad and the ugly

    Shire’s incredible revenue growth of almost 57%, helped by its $32bn acquisition of Baxalta in 2016, lifted it into the top 20 for the first time in its history. ... However, investors fear that challenges in the $11bn haemophilia market could lead to

  • Accelerating innovation Accelerating innovation

    Going global. The company’s ambitions in cancer were boosted by last year’s appointment of new CEO David Meek, who joined the firm from Baxalta where he headed up that

  • Deal Watch January 2017 Deal Watch January 2017

    Interestingly 2016 had opened with Shire's announcement that the Baxalta acquisition was going ahead resulting in one of the year's biggest headlines with its final value of £32bn.

  • A rare talent A rare talent

    The biggest of these moves was its $32bn acquisition of Baxalta, which was officially completed in June last year and elevated its position in orphan drugs, which it expects to account ... The combination of Shire and Baxalta was extremely transformative,

More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Bedrock Healthcare Communications

    Abbvie. Baxalta. Baxter. Biogen. BMS. Britannia. CareFusion. Celgene. Ipsen. Janssen. Novartis.

  • FCB Halesway

    Abbott Vascular. Cardiovascular. Endovascular. Structural Heart. Baxalta. Haemophilia. Immunodeficiency. Bayer. Radiology solutions.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics